Antitumor activity of imatinib mesylate in neuroblastoma xenografts
- 18 October 2005
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 228 (1-2), 211-219
- https://doi.org/10.1016/j.canlet.2005.02.054
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberansBritish Journal of Dermatology, 2004
- High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemiaBlood, 2004
- Tyrosine kinase receptors as attractive targets of cancer therapyCritical Reviews in Oncology/Hematology, 2003
- Neuroblastoma: biological insights into a clinical enigmaNature Reviews Cancer, 2003
- Potential Use of Imatinib in Ewing's Sarcoma: Evidence for In Vitro and In Vivo ActivityJNCI Journal of the National Cancer Institute, 2002
- Pharmacology of imatinib (STI571)European Journal Of Cancer, 2002
- PKC δ mediates ionizing radiation-induced activation of c-Jun NH2-terminal kinase through MKK7 in human thyroid cellsOncogene, 2001
- Steel Factor and c-kit Protooncogene: Genetic Lessons in Signal TransductionCritical Reviews™ in Oncogenesis, 1994
- Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling.Journal of Clinical Investigation, 1993
- Establishment and characterization of a human neuroblastoma cell lineInternational Journal of Cancer, 1989